Immune checkpoint inhibitors (ICIs) improve outcomes in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).
However, some patients remain unresponsive to treatment, necessitating further investigation into optimal therapeutic strategies and prognostic biomarkers.
This study aimed to evaluate the efficacy of various therapies and identify factors influencing overall survival (OS) in these patients.
